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matched unrelated donor (MMUD) transplant followed by a trans-
plant from a haplo-identical parent. Twelve patients received
MRD transplants, whereas 18 patients received alternative donor
transplants—11 MUD, 3 haplo-identical, and 4 MMUD. The
median age at transplant was 9 years (range 1.5 to 18.4 yrs). For
MRD transplants, the conditioning regimen most often utilized
cyclophosphamide 50 mg/kg  4 days and ATG 30 mg/kg  3
days. For alternative donor transplants, the conditioning regimen
most often utilized cyclophosphamide 50 mg/kg  4 days, Cam-
path 3-10 mg  4 days (dependent upon patient weight) or ATG
30 mg/kg  3 days, and TBI (single fraction 200 cGy for MUD;
two fractions 200 cGy for MMUD). Nine alternative donor recip-
ients received ATG in their preparative regimens, whereas 11
received Campath. GVHD prophylaxis was either FK506 or cy-
closporine  mini-methotrexate. The overall survival for MRD
patients was 91.7% versus 80% for alternative donor patients at a
median follow-up of 47 months (range 3 to 100 months). Of our 32
patients, there were 5 deaths: pulmonary failure with extensive,
chronic GVHD (n 1); poor graft function with infection (n 1);
and infection (n  3). For patients receiving alternative donor
transplants, the overall survival for the Campath group was 81.8%
vs. 77.8% in the ATG group. None of the Campath patients
developed extensive, chronic GVHD compared to 3/9 ATG pa-
tients. In conclusion, alternative donor transplantation using Cam-
path or ATG in the preparatory regimens offers a curative therapy
for pediatric SAA patients with survival similar to that of patients
receiving matched sibling transplants. Although follow-up is
shorter, Campath may be associated with a reduced incidence of
extensive, chronic GVHD and further investigation is warranted.
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HLA-MISMATCHED/HAPLOIDENTICAL BLOOD AND MARROW TRANS-
PLANTATION IN 207 CASES OF LEUKEMIA—REPORT FROM A SINGLE
TEAM
Lu, D.-P.1, Dong, L.1, Wu, T.1, Huang, X.-J.1, Zhang, M.-J.2,
Chen, H.1, Han, W.1, Liu, D.-H.1, Gao, Z.-Y.1, Chen, Y.-H.1,
Xu, L.-P.1, Zhang, Y.-C.1, Ren, H.-Y.1, Liu, K.-Y.1, Li, D.1 1Peking
University People’s Hospital, Dao-pei Hospital, Beijing, China; 2Medical
College of Wisconsin, Milwaukee, WI.
Objective: HLA-mismatched related donor blood and marrow
transplantation (BMT) is a suitable alternative approach in patients
who lack a matched donor. We hypothesized that differences in
BMT-outcome might be inﬂuenced by age, type of leukemia and
feto-maternal tolerance. Patients: Here is the report on outcomes
after mismatched related donor BMT for leukemia in patients aged
3-53 years, performed by a single team and transplanted from April
2002 to May 2005 and followed through June 2005. 65 (31%) had
CML, 57 (28%) AML, 73 (35%) ALL and 12 (6%) MDS. 46% had
early stage disease, 30% intermediate and 24% had advanced
disease at BMT. 32(16%) of grafts were mismatched at a single
HLA locus, 93 (45%) at 2 HLA loci and 82 (40%) at 3 HLA loci.
All patients received a uniform protocol (BuCy2  ATG) for
BMT. Results: All of patients achieved full engraftment. Rates of
acute and chronic GVHD were similar in children and adults, P 
.67 and P  .20, respectively. The two-year probabilities of TRM
were 19% and 22%, and those of relapse were 25% and 17% in
children and adults, respectively. Two-year probabilities of LFS
and overall survival (OS) were 55% and 62% in children, and 61%
and 65% in adults, respectively. The two-year OS in patients who
received graft from their mother, father, sibling and offspring were
61%, 66%, 76%, and 62% (P  .40), respectively. Disease status
was a signiﬁcant impact factor on the survival. Two years OS in
early, intermediate, and advanced stage at transplantation was
77%, 60% and 45% (P  .002), respectively. Multivariate analyses
resulted that in children with advanced leukemia and BMT with
female donor were associated with higher risks of relapse, treat-
ment failure and overall mortality. However, in adult recipients,
BMT with a cousin or father donor was associated with higher
treatment failure and overall mortality and ALL was associated
with higher relapse rates. Higher CD3 dose reduced the TRM.
Conclusion: Mismatched related BMT appears to be a feasible
option in patients who lack a matched donor. The avoidance of
female donors for children and use of sibling or maternal donor for
adults is likely to present a better survival after BMT. Graft-versus-
leukemia effect might play a role in the lower relapse rates seen in
patients with AML/CML rather than lymphoid malignancies.
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A MATCHED PAIR RETROSPECTIVE COMPARISON OF ADULT UNRE-
LATED AND SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTA-
TION (SCT) FOR AML
Dodds, A.J.1, Moore, J.1, Goh, K.Y.2, Bradstock, K.F.3, Szer, J.4,
Nivison-Smith, I.5, Ma, D.D.F.1 1St. Vincents Hospital, Sydney, NSW,
Australia; 2National University of Malaysia, Kuala Lumpur, Malaysia;
3Westmead Hospital, Sydney, NSW, Australia; 4Royal Melbourne Hos-
pital, Melbourne, Victoria, Australia; 5Australasian Bone Marrow
Transplant Recipient Registry (ABMTRR), Sydney, NSW, Australia.
Recent studies have shown nearly equivalent survival outcomes
for unrelated donor (URD) SCT in CML compared to sibling
donors. This study compared outcomes for a set of URD trans-
plants for AML and a strictly selected matching set of sibling donor
transplants. 105 adult histocompatible URD transplant recipients
with AML aged between 16 and 59 years at transplant were se-
lected from the ABMTRR database. 105 adult ﬁrst 6/6 HLA-
identical sibling transplants were selected, matched with the sub-
jects for disease stage, sex and age as a control group. There was no
signiﬁcant difference between subjects and controls in the distri-
butions of time from diagnosis to transplant, donor-recipient sex
match, prior therapies, donor age or performance status. The
transplants were carried out from 1992 to 2002 inclusive. The
median follow up of live subjects was 4.4 years and for live controls
was 6.3 years. There were 18 good risk (CR1) and 87 poor risk
(	CR1) recipients in both URD and sibling groups. Five-year
disease free survival (DFS) was not signiﬁcantly different for good-
risk URD and sibling donor recipients (62% vs 40%, P  .20), or
poor-risk URD and sibling recipients (21% vs 25%, P  .20). In a
multivariate Cox regression model, the independent risk factors for
DFS were disease stage beyond CR1 (P .001), age	49 (P .03)
and recipient CMV positivity (P  .007). Both neutrophil and
platelet engraftment were signiﬁcantly more rapid in the sibling
group but transplant related mortality at 100 days was not signif-
icantly different. There was no difference in the cumulative inci-
dence of acute GVHD grade II or above at 100 days. The cumu-
lative incidence of chronic GVHD at 1 year post transplant was
greater in good risk URD transplants compared to controls (84%
vs 61%; P .04) but not poor risk transplants. Relapse occurred in
28% of good risk URD subjects and 16% of siblings (P  .30)
while in poor risk subjects this was 39% and 29% (P  .20). Adult
URD allograft recipients for good and poor risk AML in this study
had equivalent DFS probability to sibling recipients. This study
provides a rationale for a larger prospective study of risk factors in
allogeneic transplantation for AML. The ABMTRR is an impor-
tant national data resource providing a large and readily accessible
sample frame for retrospective studies.
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NEW TREATMENT MODALITY BY ADOPTIVE TRANSFER OF CHIMERIC
CELLS FROM TWO DIFFERENT MHC MISMATCHED DONORS
Siemionow, M., Klimczak, A., Agaoglu, G., Jankowska, A., Kulahci, Y.
The Cleveland Clinic Foundation, Cleveland, OH.
Background: Donor bone marrow transplantation (BMT) may
promote chimerism in solid organ and composite tissue allografts.
This study was designed to evaluate the rationale of immunother-
apy with adoptive transfer of donor-speciﬁc cells originated from
two different MHC mismatched donors and transplanted to the
same recipients. Methods: Seven primary trimera were created
across the MHC barrier from LBN (RT1n) (n  7) and ACI
(RT1a) (n  7) donors to LEW (RT1l) recipients (n  7), under a
7-day protocol of 
-TCRmAb/CsA therapy. Bilateral intraosse-
ous BMT (70 106) was performed from LBN and ACI donors to
left and right femur respectively. Fourteen secondary trimeras
were created via adoptive transfer of MACS-sorted primary chi-
meric cells: double positive RT1n/RT1a cells (9.0  106 to 24.0 
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106 transplanted unilaterally) and single positive RT1n (4.5  106
to 9.0 106) and RT1a (6.0 106 to 12.0 106) cells transplanted
bilaterally to naive Lewis rat. Donor-speciﬁc chimerism (for MHC
class I antigens) and efﬁcacy of MACS sorting was assessed by ﬂow
cytometry. Therapeutic effect of adoptive transfer of donor chi-
meric cells was evaluated following bilateral transplantation of skin
ﬂaps of donor origin (LBN and ACI). Results: In primary trimeras
13.1% of LBN donor positive cells (RT1n) and 6.8% of ACI donor
positive cells (RT1a) was found. MACS-sorting revealed 87%-96%
purity of double positive RT1n/RT1a cells. At day 21 secondary
trimera created via double positive cell transplantation (RT1n/
RT1a) revealed 8.3% of RT1n and 11.3% of RT1a positive cells,
whereas injection of single positive cells (RT1n and RT1a) resulted
in 6.0% of RT1n and 7.6% of RT1a chimerism. Prolonged skin ﬂap
survival was achieved over 84 days after double positive RT1n/
RT1a transplant and over 120 days in single positive chimeric cells
recipients (still under observation). Conclusions: Intraosseous
transplantation of bone marrow from two different MHC mis-
matched donors under a 7-day 
-TCRmAb/CsA protocol re-
sulted in creation of donor-speciﬁc trimera. Isolation and adoptive
transfer of chimeric cells proved to be efﬁcacious in extension of
donors skin ﬂap survival without prolonged immunosuppression.
70
BONE MARROW TRANSPLANTATION (BMT) FOR HEAVILY TRANS-
FUSED PATIENTS (pts) WITH SEVERE APLASTIC ANEMIA (SAA): 147
PTS TREATED AT THE SAME INSTITUTION WITH BUSULFAN (BU) 
CYCLOPHOSPHAMIDE (CY)
Bonﬁm, C., Bitencourt, M., Funke, V., Setubal, D., Ruiz, J., Doro, M.,
Medeiros, C.R., Zanis-Neto, J., Pasquini, R. Federal University of
Parana, Curitiba, PR, Brazil.
BMT from HLA identical siblings is currently the best treatment
for young pts with SAA. However, heavily transfused pts have an
inferior survival due to an increased risk of rejection and transplant
related mortality (TRM). In developing countries not only the
number but the quality of pretransplant transfusions should be
considered because most of them are not ﬁltered or irradiated. In
1993 we introduced BU to the preparatory regimen of pts with
more than 15 pretransplant transfusions trying to reduce the ele-
vated incidence of rejection observed in pts receiving only CY. In
this study we retrospectively analyzed the results in 147 pts trans-
planted between 01/93-01/05 with BU  CY. Age: 2-46 y (M: 19).
Previous blood transfusions: 15-675 (M: 34 UI). Disease duration:
1-114 mo (M: 4). All pts received bone marrow from HLA iden-
tical siblings. Preparatory regimen: BU 12 mg/kgCY 120 mg/kg.
GVHD prophylaxis: cyclosporine  methotrexate. TNC infused:
1.17-6.55  108/kg (M: 3.01). Immediately prior to BMT, 39 pts
(26%) had active bacterial or fungal infections. One hundred and
four pts are alive with a median follow up of 2719 days (range:
189-4506). Eight pts died before day 28 and were not evaluable
for engraftment. Primary graft failure (GF) occurred in 4/139 pts
(2.8%) and all pts died. Late GF occurred in 19/135 pts (14%)
between 207-1448 days after BMT (M: 584 days). 10/19 pts are
alive (5 after a 2nd BMT and 5 after treatment with immune
suppression). Mucositis grade III-IV occurred in 80 pts (54%).
VOD: 2 pts. Hemorrhagic cystitis: 13 pts (8.8%). Acute GVHD
grade II-IV: 20/135 pts (III-IV: 11 pts—8%). Chronic GVHD:
22/128 pts (extensive: 16 pts—12.5%). Forty-three pts died be-
tween 10-3072 days after BMT (M: 154 days). Death was mainly
related to infections or bleeding. 17 pts died before day 100 and
76% of them had severe infections prior to transplant. 11/16 pts
with extensive chronic GVHD died. Pts with more than 50 previ-
ous blood transfusions had an inferior survival when compared to
those receiving between 15-50 UI (54%  74%; P  .005). 28 pts
are surviving more than 10 y after BMT with a satisfactory quality
of life. We conclude that the use of BU  CY reduced the risk of
rejection in this group of pts. Survival reached 70% in pts receiving
between 15-50 transfusions. Alternative preparatory regimens
could be offered to pts receiving 	50 UI before transplant. Infec-
tions immediately prior to conditioning increased the risk of TRM.
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THERAPEUTIC ANTI-TUMOR IMMUNITY MEDIATED BY TRANSIENTLY
ENGRAFTING ALLOGENEIC LYMPHOCYTES: THE “ALLOGENEIC EF-
FECT” REVISITED
Symons, H.J., Levy, M.Y., Wang, J., Zhou, X., Fuchs, E.J. Sidney
Kimmel Comprehensive Cancer Center, Baltimore, MD.
The “allogeneic effect” refers to the induction of host B cell
antibody synthesis or host T cell cytotoxicity, including tumori-
cidal activity, by an infusion of allogeneic lymphocytes. We have
previously shown that treatment of mice with cyclophosphamide
(Cy) followed by infusion of CD8 T cell-depleted allogeneic
spleen cells (Cy  CD8 DLI) induces anti-tumor activity in a
model of minimal residual leukemia, even though the donor cells
are eventually rejected by the host immune system. The purpose of
the current investigation was to test the activity of Cy  CD8
DLI in the treatment of well-established cancer, and to character-
ize the mechanisms of the anti-tumor effect. BALB/c mice were
inoculated intravenously (IV) with the syngeneic A20 lymphoma/
leukemia or the RENCA renal cell carcinoma on day 0 and were
then treated with nothing, Cy alone on day 14, or Cy  CD8
DLI from MHC-mismatched C57BL/6 donors on day 15. In both
tumor models, the combination of Cy  CD8 DLI signiﬁcantly
prolonged survival compared to mice treated with nothing or with
Cy alone. While depletion of CD4 T cells from the DLI signif-
icantly diminished the beneﬁcial effect of CD8 DLI, puriﬁed
CD4 T cells alone were inactive, demonstrating that donor
CD4 T cells and another population of cells were required for
optimal anti-tumor activity. Several observations pointed to an
active role for the host immune system in the anti-tumor activity of
CyCD8DLI. First, host T cells participated in the anti-tumor
effect of treatment with Cy alone, since the drug’s activity was
diminished in tumor-bearing scid mice or in normal BALB/c mice
depleted of T cells. Second, while Cy  CD8 DLI caused no
GVHD in tumor-bearing but immunocompetent BALB/c recipi-
ents, it caused fatal acute GVHD in either tumor-bearing scid or
T-cell depleted BALB/c mice. Finally, the anti-tumor effect of Cy
and Cy  CD8 DLI was also signiﬁcantly inhibited in BALB/c
mice depleted of CD8 T cells. These results demonstrate that
transiently engrafting T cells administered after Cy can induce
signiﬁcant anti-tumor effects against solid and liquid tumors. We
propose that upon recognition of alloantigen on host antigen-
presenting cells (APCs), allogeneic donor CD4 T cells deliver
activating ligands to the APCs, thereby generating effective “help”
to break tolerance in tumor-speciﬁc host CD8 T cells. This
mechanism may correspond to the “allogeneic effect” in the anti-
tumor response described over three decades ago.
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TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)—IMPACT OF
NON-RELAPSE MORTALITY ON OUTCOMES
Ativitavas, T.1, Saliba, R.2, Sergio, G.2, Ghosh, S.2, Champlin, R.2,
de Lima, M.2 1Mahido University, Bangkok, Thailand; 2Department of
Blood and Marrow Transplantation, Houston, TX.
Introduction: Myelodysplastic syndromes (MDS) are clonal he-
matopoietic disorders potentially curable with allogeneic HSCT.
Non-relapse mortality (NRM) is a major cause of treatment failure
in this context. Preparative regimens may impact survival (S) dif-
ferently given dissimilar toxicity rates. We investigated this hy-
pothesis in a dataset of patients with MDS (as deﬁned by WHO
criteria) treated in our institution from January 1993-December
2004.Methods:We reviewed 88 patients (65% males); 30 patients
(34%) received induction chemotherapy prior to HSCT (4 RA, 4
RARS, and 22 RAEB) and 58 patients (66%) did not (30 RA, 3
RARS, 21 RAEB, and 4 refractory cytopenia). Median age was 50
years (20-69). IPSS was high risk in 27%, intermediate 2 in 40%,
intermediate 1 in 28%, and low in 5%. Cytogenetics were poor in
52%, intermediate in 17% and good in 31% of patients. 53 patients
(60%) were treated with myeloablative regimens including 12 Gy
TBI-based (11/53), Bu/Cy (17/53) and Bu/Flu (25/53). 35 (40%)
patients were treated with reduced intensity regimens (Flu/Mel,
FAI or low-dose busulfan/Flu). Donor was matched-related in
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